7 TIMES SQUARE, NEW YORK, NY
Executive Compensation Agreements Amended for Stergiou, Burns, and Cicic
Annual Meeting of Stockholders Held; Five Proposals Voted On
SELLAS Life Sciences Reports $28.7 Million from Warrant Exercises
Reports First Quarter 2026 Financial Results and Provides Corporate Update
Annual Report to Security Holders
Reports Full Year 2025 Financial Results and Provides Corporate Update
SELLAS Life Sciences Secures $42.6 Million from Warrant Exercises
SELLAS Life Sciences Reports $71.8M Cash Position and $26.5M from Warrants
Q1
FY 2025
Q3
Q2
FY 2024
Registration Statement for Securities to be Offered to Employees
S-3ASR
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
Correspondence
Submission Upload